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Abstract
Multidrug-resistant bacteria (MDR) are spreading rapidly across the world that outpace 
development of new antibiotics. Options other than antibiotics treatment are urgently 
needed. In this chapter, we review the current status of nonantibiotics-based strategies 
including phage therapy and phage-derived protein therapy for targeting Gram-positive 
strains (methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus 
faecium) and MDR Gram-negative strains (Acinetobacter baumannii and Pseudomonas 
aeruginosa).
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1. Introduction
Host-pathogen battle is a never ending theme regarding infection and immunity. Human 
innate immune defense is triggered at early stages of bacterial infections. As the major players 
of innate immunity, macrophages, neutrophils, dendritic cells (DCs) and natural killer cells rec-
ognize pathogen-associated molecular patterns (PAMPs) and damage (or danger)-associated 
molecular patterns (DAMPs) through their pattern recognition receptors (PRRs) [1–3].
Known PRRs consist of Toll-like receptors, C-type lectin receptors, Nod-like receptors (target-
ing intracellular pathogens via inflammasome), AIM2-like receptors, RIG-I-like receptors and 
microbial nucleic acid sensors [1, 4, 5]. Identified PAMPs include lipopolysaccharide (LPS 
or endotoxin), peptidoglycan, lipoteichoic acid, exotoxin, effector protein, lipoprotein, porin, 
flagellin, pilin, glycoprotein, glycosylphosphatidylinositol, microbial nucleic acid and outer 
© 2018 The Author(s). Licensee InTech. This chapt r is distributed under the terms of the Creative Comm s
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membrane vesicle (extracellular vesicle or exosome) [1, 4, 6, 7]. Activation of innate immune 
systems through interactions of PAMPs and DAMPs with PRRs induces antigen presenting 
cells (APCs, mainly macrophages and DCs) to phagocytose bacterial pathogens and cleave 
pathogen-related proteins to peptides within endosomes and lysosomes [8]. The cleaved pep-
tides can be recognized by major histocompatibility complex (MHC)-II and presented to the 
surface of APCs. MHC-II-peptide complex is the natural ligand of T-cell receptor (TCR) from 
CD4+ T cell that can stimulate cytokine and chemokine secretion, inflammatory signaling cas-
cade and activate adaptive immune responses from both T lymphocytes and B lymphocytes 
for protective immunity and elimination of pathogens [1, 4, 8].
On the other hand, bacteria evolve strategies to compromise, manipulate or evade host 
immune system that can lead to host cell autophagy and pyroptosis and thus enhance bacte-
ria adhesion, colonization and chances of survival within the host [9, 10]. Moreover, excessive 
or chronic inflammations induced by bacterial infections are closely related with pathogen-
esis of autoimmune disorders [11]. Thus, effective treatment of bacterial infections is urgent. 
However, multidrug-resistant bacteria (MDR) appear to outpace current development of new 
antibiotics, especially to six frequently reported MDR bacteria, designated as Enterococcus 
faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeru-
ginosa, Enterobacter spp. (ESKAPE) [12, 13].
Staphylococcus aureus (S. aureus) is a Gram-positive, leading nosocomial pathogen that can 
cause many types of infections, ranging from surgical site infections from intensive care units 
(ICUs) to community-acquired skin and soft tissue infections. Methicillin-resistant S. aureus 
(MRSA) became endemic in hospitals by the 1980s and in some areas, more than 50% of S. 
aureus isolates are now resistant to methicillin [14]. In the United States, an estimated 80,000 
invasive MRSA infections and 11,000 related deaths occur annually [15].
Enterococci are Gram-positive, facultatively anaerobic cocci that often occur in chains of vari-
ous lengths. Enterococci are generally considered as low virulent as evidenced by their natu-
ral presence in human gastrointestinal tract and long being used as probiotics in human. 
They have attracted more attention since increasing number of patients who are immunosup-
pressed or receiving antimicrobial agents have been reported to suffer from MDR Enterococci 
infections [16]. In fact, an estimated number of 20,000 cases and 1300 deaths are caused by 
vancomycin-resistant E. faecium (VRE) infection annually in United States [17].
Pseudomonas aeruginosa (P. aeruginosa) is a Gram-negative, leading cause of nosocomial infec-
tions and shows potential of rapid evolution of antibiotics resistance during therapy [18]. 
Susceptible individuals include victims of cystic fibrosis and those with an impaired immune 
system caused by HIV infection, organ transplantation, cytotoxic drugs or burns with vascu-
lar damage [19].
Acinetobacter baumannii (A. baumannii) is a Gram-negative, drying and disinfectant-resistant 
bacterium that can evade human immunity and develop drug resistance to almost all classes 
of antibiotics [20, 21]. MDR A. baumannii infection is mainly restricted within hospitals for 
patients with mechanical ventilation, burns, wounds, sepsis, meningitis and often leads to 
high morbidity and mortality [20, 22, 23].
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Bacteriophage (short for phage), as its name indicates, is a natural virus that only infects 
bacteria and this unique property makes bacteriophage an attractive alternative for bacte-
rial infection treatment, especially for the current MDR bacteria spreading worldwide. This 
chapter reviews the current status of phage therapy and phage-derived protein therapy for 
Gram-positive strains including MRSA and VRE and MDR Gram-negative strains (A. bauman-
nii and P. aeruginosa).
2. Lytic bacteriophage structure
Phages are estimated to be the most diverse and abundant entity on earth that exist in every 
ecosystem with the range of 1030–1031 and are about 10 times more than their bacterial hosts 
[24]. For instance, agricultural soils usually harbor a phage count of approximately 108–109 
per gram of dry soil and aquatic environments contain a phage titer of 104–108/mL [25–28].
The basic phage structure is made up of a hexagonal head, which harbors the phage double-
stranded DNA (dsDNA), together known as capsid, a tail and a connector between head and 
tail (Figure 1A) [29]. The head is anchored to a tail sheath via a neck and a collar and ends 
into a hexagonal base plate. Tail fibers/spikes emerge from the base plate and the tail sheath 
tapers into a tail tube.
Figure 1. Structure and life cycle of a lytic bacteriophage. (A) The structure of a typical lytic bacteriophage is shown. 
(B) Lytic phage life cycle is shown starting with attachment on bacterial cell surface and proceeding to phage release by 
intermediate steps.
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Phages are classified into two categories (lytic and nonlytic or temperate) and 13 families 
based on certain criteria including its host specificity, morphology, genotype, infective mode, 
with or without envelope and lipid [30]. Currently, over 5500 different bacteriophages have 
been sequenced and 96% of them, including most of therapeutic phages, belong to the order 
Caudovirales [31]. The order Caudovirales comprises three families according to the morpho-
logical features of the tail: Myoviridae (with long, rigid, contractile tails, e.g. T4), Siphoviridae 
(with long, flexible, noncontractile tails) and Podoviridae (with short, noncontractile tails).
3. Lytic bacteriophage life cycle
Lytic bacteriophages are of special interest in phage therapy of bacterial infections. Lytic 
phage life cycle typically consists of (1) Attachment/adsorption to the host cell—it involves 
the contact between tail fibers and the host cell receptors like lipopolysaccharide (LPS), pep-
tidoglycan (PG), outer membrane (OM), fimbriae, flagellum or sex pilus; (2) Injecting phage 
DNA—the phage secretes specialized enzymes that destroy the LPS, PG and OM to inject the 
phage DNA through the tail tube into the host cell; (3) Phage DNA replication—after phage 
DNA injection, phage early genes are expressed which take the control of host cell machinery 
to replicate phage DNA. The replicated phage DNA then expresses phage late proteins nec-
essary for virion assembly; (4) Assembly and packing of phage particle—once the assembly 
proteins are expressed, capsid assembles by encapsulating the phage genetic material and 
later a separately assembled tail joins the capsid to make a full phage particle; and (5) Host 
cell lysis and phage release—the phage late proteins comprise endolysins and holins which 
together break the PG layer, lyse the bacteria and burst out the fully formed bacteriophage 
into the environment [32, 33]. Figure 1B illustrates a cartoon process of how bacteriophage 
infects, lyses bacteria and releases progeny. Since the lytic phage kills the bacterial host cell 
after completing the lytic life cycle, they are seen as potential antibacterial agents.
4. Phage therapy against MRSA
More than 200 lytic phages against S. aureus have been characterized [31]. Most of S. aureus 
phages belong to the Siphoviridae, such as lytic phage φMR11 [34] and lytic phage phiIPLA35 
[35]. A small number of S. aureus phages belong to the Podoviridae like SAP-2 phage [36] and 
Myoviridae like Stau2 [37] and well-known phage K [38].
Development of phage resistance to host-pathogen and cross-resistance with antibiotics are 
seldomly observed [39]. Thus, MRSA pathogens can be targeted by the anti-S. aureus phages 
such as phage K and φMR11 [34, 40]. φMR11, administrated intraperitoneally, appeared rap-
idly in the circulation of mice challenged with fatal S. aureus infection and successfully pro-
tected mice without any adverse effects [34].
S. aureus-specific phage MR-10, when combined with Mupirocin, can not only significantly 
reduce the in vitro adherence, invasion and cytotoxicity of MRSA on murine nasal epithelial 
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cells and effectively eradicate MRSA population from mouse nares but also decrease the fre-
quency of mutation coupled with Mupirocin treatment alone to negligible levels [41]. Similarly, 
synergistic effect on anti-S. aureus was observed when combination of S. aureus phages with 
gentamicin or linezolid was used [42, 43].
Biofilms play a key pathological role in S. aureus-associated chronic infections [44]. Bacteriophage 
cocktail NOV012 containing two different phages, P68 and K710, showed high protection against 
MRSA-related chronic rhinosinusitis [44]. Moreover, Poland scientists demonstrated that effi-
cient phage therapy was an alternative to antibiotics for treating chronic MRSA infections with 
significant savings in healthcare costs [45].
Interestingly, researchers found that some S. aureus-specific lytic phages, identified from 
natural sewage, showed higher protective efficiency against MRSA in mice than antibiotic or 
conventional phage and antibiotic combined treatment [46, 47].
To overcome the rapid release of toxics arising from lytic phage induced S. aureus lysis, the 
endolysin gene controlling the release of phage progeny was inactivated in S. aureus phages. 
These lysis-deficient phages successfully induced MRSA death in mice infection model with-
out lysis induced side effects such as septic shock or toxic shock syndrome, possibly based on 
the sole activity of holin [48, 49].
Phage can be used as an efficient carrier to bring photosensitizers (light-activated antimi-
crobial agents) to S. aureus by chemical conjugation which then resulted in enhanced and 
selective killing of MRSA when exposed to low-dose red light [50]. Moreover, as the carrier 
for photosensitizers, the ability to selectively kill MRSA is independent of phage’s ability to 
infect S. aureus [51].
5. Phage therapy against VRE
More than 27 phages have been isolated and tested for their protective efficacy VRE infection 
[52]. Most of these phages belong to the Myoviridae or the Siphoviridae families [52]. Phage 
ENB6, isolated from raw sewage, has lytic activity against a wide range of clinical VRE iso-
lates and single dose of intraperitoneal injection was sufficient to rescue 100% of the fatally 
infected mice [53]. The authors also demonstrated that the ability of this phage to rescue 
bacteremic mice was not due to a nonspecific immune effect but due to the ability of phage 
ENB6 itself [53]. Similarly, in vivo therapeutic potential of virulent phage phiEF24C, evalu-
ated in a sepsis BALB/c mouse model, proved to be effective against lethal VRE infection at 
a low concentration following a single or repeated phage exposure [54]. Enterococcus faecalis 
phage IME-EF1 was isolated from hospital sewage; when administrated intraperitoneally in a 
murine sepsis model, one dose of IME-EF1 or its endolysin was found to reduce the bacterial 
blood count and protect the mice from a lethal challenge of E. faecalis [55]. Biofilm-associated 
VRE infections are challenging for treatment. EFDG1, isolated from sewage water, was effi-
cient not only in nearly eliminating 2-week old E. faecalis biofilms of around 100 μm thickness 
but also in prevention of E. faecalis root canal infection [52, 56].
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6. Phage therapy against MDR P. aeruginosa
More than 110 phages specifically target P. aeruginosa and around 60% are lytic phages, which 
are frequently isolated from hospital wastewater and sewage wastewater [57]. Fu et al. [58] 
used an in vitro model to investigate the effect of lytic phages in the prevention of P. aeruginosa 
biofilm formation in hydrogel-coated catheters and found that catheters, when pretreated 
with single phage, presented high reduction of biofilm formation at early inoculation while 
cocktail phage treatment in keeping high reduction of biofilm formation lasted over 48 hours 
post treatment.
Torres-Barceló et al. [59], Knezevic et al. [60], Zhang and Hu [61] and Oechslin et al. [62] explored 
the combinatorial effect of phages with different antibiotics against P. aeruginosa and found that 
certain combination can lead to synergistic effect than single treatment alone. Moreover, Torres-
Barceló et al. found that long-term combination of phages with antibiotics not only showed 
synergistic benefit but also weakened antibiotics-induced resistance for P. aeruginosa when used 
alone [63].
A mouse lung infection model was used to evaluate therapeutic and prophylactic efficiency of 
phage PAK-P1 against MDR P. aeruginosa by nasal. The curative treatment of one single dose 
2 hours after bacterial infection allowed over 95% survival and preventive treatment with 
single dose 4 days before infection resulted in 100% survival whereas untreated mice all died 
within 2 days after infection [64].
To evaluate efficacy and safety of bacteriophage therapy in human, Wright et al. used a phage 
cocktail named as Biophage-PA to carry out the first controlled clinical trial phase I/II for 
treating MDR P. aeruginosa that caused chronic otitis in 2009 [65]. Encouragingly, Biophage-
PA-treated patients showed significant clinical improvements and no related side effects or 
local systemic toxicities when compared with placebo control individuals [65].
7. Phage therapy against MDR A. baumannii
Phage AB1 and phageφAB2, as the early characterized phages in detail against MDR A. bau-
mannii, were reported in 2010 [66, 67]. Phage AB1 belongs to the Siphoviridae family and harbors 
a narrow host range, a latent period of 18 minutes and a burst size of 409, whereas phage φAB2 
is from the Podoviridae family, showing rapid adsorption (more than 99% absorbed in 6 min-
utes), a latent period of less than 10 minutes, a burst size of around 200 and a broad host range 
[66, 67]. Furthermore, phageφAB2 was shown to be used potentially as an anti-MDR A. bauman-
nii hand wash [68]. Two A. baumannii-specific lytic phages, AB7-IBBI and AB7-IBB2, belonging 
to the Siphoviridae family and the Podoviridae family, respectively, demonstrated the ability to 
remove approximately 75% of preformed biofilms of MDR A. baumannii and showed potential 
application in hospital as environmental biocontrol agent [69, 70]. vB_AbaM-IME-AB2, a novel 
lytic A. baumannii phage, belongs to the Myoviridae family with a latent period of 20 minutes 
and a burst size of 62 and can infect MDR clinical isolates of A. baumannii [71].
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Mouse infection model-based studies showed that BS46, a specific A. baumannii phage, could 
protect mice infected intraperitoneally with five times the lethal dosage 50 (LD50) of a highly 
virulent A. baumannii strain [72]; and a five-membered A. baumannii-specific phage cocktail 
demonstrated therapeutic efficacy against MDR A. baumannii pathogen in an infected wound 
model [73].
Eight lytic phages, isolated from hospital sewage, can lyse 34 clinical A. baumannii strains with 
various spectrums [74]. One phage named as φkm18p, belonging to the Podoviridae family, 
showed potent lysis of 15/34 clinical A. baumannii strains, of which many were “extensively 
drug resistant” A. baumannii strains [74]. The authors suggested that a cocktail of φkm18p 
with other lytic phages has potential to treat all MDR A. baumannii strains [74].
Recently, other lytic phages or phage cocktails have been reported to have potentials for 
treatment of A. baumannii infections in ICUs including vB_AbaM_Acibel004 and podo-
virus vB_AbaP_Acibel007 [75], phage Bϕ-C62 [76], vB-GEC_Ab-M-G7 [77] and vB_AbaM-
IME-AB2 [78]. Of note, cleaning of ICUs with addition of active phage aerosol significantly 
reduced A. baumannii infection rate and consumption of antimicrobials [79], highlighting 
the potential of phage-based prevention and therapy against MDR A. baumannii in the near 
future.
8. Bacteriophage derived proteins as antibacterial biologics
Bacteriophage encodes specialized proteins that mediate the phage entry into and exit out 
of the bacterial host during the lytic cycle. These phage proteins/enzymes are critical for 
both disintegration of the physical barrier and exploiting physiological pathways to estab-
lish an infection. The bacterial cell wall comprises an outer membrane exopolysaccharides 
(OM-EPS) and inner membrane peptidoglycan (IM-PG), which serves as the target of vari-
ous phage enzymes. Therefore, phage enzymes are perceived as “natural antibiotics” but 
the idea itself has remained in its infancy due to the largely popular and broadly effec-
tive antibiotic drugs. However, a growing number of MDR bacterial pathogens have rung 
the alarm and triggered a renewed interest in employing phage-derived proteins to treat 
bacterial infections. In this section, we will focus on the phage lysins, which enzymati-
cally cleave the linkages in the peptidoglycan (PG) layer of the bacterial cell wall. The PG 
layer is made up of alternating N-acetylglucosamine (GlcNAc) and N-acetylmuramic acid 
(MurNAc) units in which the MurNAc residues are covalently linked via amide bonds to 
the L-alanine of the stem peptide [80]. The PG layer provides the structural integrity and 
rigidity to bacterium and its breakdown is essential for phage to enter and exit its host cell 
(Figure 2). Based on their temporal expression, phage lysins can be divided into two types: 
(1) virion-associated peptidoglycan hydrolases (VAPGHs) and (2) endolysins. Figure 3 
shows overall architecture of VAPGHs and endolysins. We present an overview of phage 
lysin function and therapeutic potential in treating bacterial infections. We also present the 
protein engineering strategies employed to enhance bacteriolytic property and tropism of 
such proteins.
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8.1. Virion-associated peptidoglycan hydrolases (VAPGHs)
VAPGHs are phage encoded hydrolytic enzymes which specifically degrade the PG layer of 
both Gram-positive and negative bacteria. VAPGHs are expressed early in the phage life cycle to 
degrade the OM for phage attachment and subsequent adsorption. These enzymes can have wide 
occurrence since the PG layer is common to both Gram-positive and Gram-negative bacteria. 
Figure 2. Bacterial cell wall degradation by phage enzymes. The bacteriophage enzymes comprising endolysin and holin 
together facilitate the degradation of the host bacterial cell-wall lysis by cleaving specific linkages in peptidoglycan layer 
and plasma membrane of (A) Gram-positive bacterial and (B) Gram-negative bacterial cell wall.
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However, it is thicker in Gram-positive organisms (20–80 nm) when compared to Gram-negative 
bacteria (10 nm) [80]. Different phage proteins can have various muralytic activities and their loca-
tions vary on the phage structure [81–83]. The VAPGH genes, although are not critical for phage 
multiplication, can ease out the phage infection process during suboptimal conditions [84, 85], 
against bacteria possessing an extensively cross-linked PG layer [83, 86] or if phage lysozyme 
activity is inhibited [87].
The muralytic activity of VAPGHs resides in the N-terminal and the cell wall/cell binding 
domain (CWBD/CBD) is present at the C-terminal (e.g. in a broad-spectrum staphylolytic 
phage P68 VAPGH P17) [88]. Owing to their modular architecture, VAPGHs can be engi-
neered to enhance lytic activity and increase the tropism. A chimeric VAPGH P16-17 with 
N-terminal endopeptidase domain of Lys16 and the C-terminal CWBD of VAPGH P17 exhib-
its staphylolytic activity [89]. Chimeric versions of VAPGH HyDH5 and Lys16, produced by 
C-terminal fusion of bacteriocin lysostaphin SH3bCBD or a direct fusion of cysteine/histi-
dine-dependent amidohydrolases/peptidase (CHAP) domain to SH3bCBD in the absence of 
enzymatically active domain (EAD), improve the lytic activity against S. aureus including 
MRSA, S. epidermis and S. carnosus [90–92]. This increased staphylolytic activity and tropism 
are attributed to the dual enzymatic activities targeting distinct linkages within the PG layer 
[90]. Similarly, S. aureus-specific temperate phage DW2 codes a hydrolytic VAPGH THDW2. 
This enzyme has a modular structure with N-terminal CHAP domain and an EAD at the 
C-terminal but lacks the CWBD/CBD [93].
8.2. Endolysins—phage enzymes degrading peptidoglycan
Endolysins are also muralytic enzymes like VAPGHs coded by dsDNA phage. Unlike VAPGHs, 
which act to degrade PG layer for phage DNA entry, endolysins are responsible for the release 
of the progeny phage late during the lytic phage cycle [94, 95]. Endolysins can be structurally 
divided into (1) globular endolysins which are constituted by a single catalytic domain (CD) 
Figure 3. Domain architecture of phage muralytic enzymes. CHAP: cysteine/histidine-dependent amidohydrolases/
peptidase; CD: catalytic domain; EAD: enzymatically active domain; CBD/CWBD: cell/cell wall binding domain.
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[83, 96]; (2) modular endolysins which are constituted by an N-terminal CD and a C-terminal 
CWBD/CBD [83, 97] and (3) three-domain endolysins which are constituted by CD, CWBD/
CBD and an additional EAD in between CD and CBD [98]. The CD of different endolysins 
may have different enzymatic activities to cleave distinct linkages in the PG layer, whereas 
the CWBD is mainly responsible for imparting specificity of the interaction which can even be 
restricted to a particular serovar [99]. They can be further classified according to their function-
ality into (1) N-acetyl-β-D-muramidases with activity against MurNAc-GlcNAc linkages; (2) 
lytic transglycolases, which cleave N-acetylmuramoyl-β-1,4-N-acetylglucosamine bond; (3) 
N-acetyl-β-d-glucosaminidase cleaving the N-acetylglucosaminyl-β-1,4-N-acetylmuramine; 
(4) N-acetylmuramoyl-l-alanine amidases, which break amide bond between sugar and pep-
tide and (5) endopeptidases, which cleave the peptide bond between two amino acid residues 
of the stem [94, 100].
The bactericidal property of the endolysins makes them attractive drug candidates to treat 
bacterial infections [101]. Artificial inoculation of S. aureus in human nares was shown to be 
completely cleared by intranasal administration of MV-L endolysin of phiMR11, a phage 
specific for S. aureus [102]. Similarly, nasal/oral administration of CHAP domain of endoly-
sin LysK eliminated S. aureus from nares of the infected mice [103]. The modular structure 
of the endolysins targeting Gram-positive bacteria is appropriate to evolve into efficacious 
drugs. A chimeric lysozyme ClyS, developed by fusing Ply Twort endolysin EAD and phi13 
phage NM3CBD, reduced MRSA from nasal passage and showed better effect than mupiro-
cin treatment [104, 105]. Furthermore, combination therapy of endolysin and antibiotics can 
be more effective in relieving MRSA infection [104]. Domain swapping strategy has also been 
used to replace the CBD of a phage endolysin PlyPSA and Ply187 to enhance the lytic ability 
when compared to their parental proteins [106]. Even the lytic spectrum of these enzymes 
can be broadened by engineering CBDs from different endolysins [106]. A Staphylococcus 
phage endolysin P128 is currently being investigated for intranasal administration against 
S. aureus in phase III clinical trials [107] and PlySs2 endolysin (CF-301) is also being tested 
against S. aureus for safety in phase I [108]. Recently, SAL-200 endolysin, derived from staph-
ylococcal phage SAP-1, is the first intravenously administered lysin, which showed good 
tolerance with no serious adverse effects in phase I safety studies [109, 110].
In 2012, Lukacik et al. showed that the fusion of FyuA-binding domain of pesticin and T4 lyso-
zyme utilizes FyuA for transport across the OM of Gram-negative Yersinia pestis [111]. This 
hybrid toxin killed Yersinia and Escherichia coli strains and also bypassed the pesticin immu-
nity (PIM) [111]. Furthermore, Ply187-derived CD, when fused to non-SH3b CBD from phage 
phi13 endolysin NM3, protects mice against MRSA [112]. Endolysins harboring SH3b CBD 
were reported to ensure 100% survival when compared to oxacillin and vancomycin in bac-
teremia model [113]. An important vision harming disease called endophthalmitis, in which 
S. aureus colonizes the eye, was treated effectively in mouse model by chimeric endolysin 
Ply187AN-KSH3b [114]. Native CD and CWBD were joined via a linker to develop chimeoly-
sins (e.g. Lys168-87, Lys170-87, B30-182-lyso, Ply187N-V12C and ClyR), which showed broad 
antibacterial spectrum [112, 115]. One such chimeolysin, ClyR, effectively lyses Streptococcal 
spp. (S. pyogenes, S. agalactiae, S. dysgalactiae, S. equi, S. mutans, S. pneumoniae, S. suis and S. 
uberis), E. faecalis and S. aureus, including MRSA [115]. The chimeolysin ClyR is also effective 
in killing Streptococcus mutans, which colonizes as biofilm on tooth surface [115].
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A shortcoming of natural endolysins is their inability to cross the OM of Gram-negative sp. (e.g. 
P. aeruginosa, Salmonella typhimurium, Salmonella enterica, A. baumannii, E. coli, S. aureus and Bacillus 
subtilis) [96, 97, 116]. Gram-negative bacteria have OM which is composed of lipopolysaccharide 
(LPS) and is only permeable to molecules smaller than 600 Da [117]. But recently, a Gram-negative 
endolysin SPN1S has shown to carry muralytic and glycosidic hydrolase activities in its alpha-
helical structure [118]. To effectively penetrate OM of Gram-negative bacteria, endolysins have 
been fused to LPS-destabilizing polycationic peptides (PCNPs) to generate “Artilysins” [119]. The 
polycationic peptides can be fused to either N- or C-terminal of the endolysins but artilysins with 
N-terminal peptide are generally more effective [119]. Different LPS-destabilizing peptides, pro-
viding varying degrees of effectiveness, have been tested in artilysin constructs with polycationic 
peptide (PCNP) being the most effective one [119, 120]. The polycationic peptide punctures the 
LPS layer and facilitates the endolysin penetration into the OM, which subsequently degrades 
the PG layer [119]. An artilysin “Art-175” is a fusion product of KZ144 endolysin of P. aeruginosa 
phage phiKZ and sheep myeloid 29 amino acid peptide (SMAP-29) which can kill P. aeruginosa 
by more than 5 log in 30 minutes [119, 120]. Similarly, N-terminal fusion of PCNP to OBPgp276 
endolysin (LoGT-001) of P. fluorescens phage OBD or PVP-SE1gp146 endolysin (LoGT-008) of 
S. enterica phage PVP-SE1 reduces P. aeruginosa by 4–5 log in 30 minutes [119]. Fusion of PCNP 
via C-terminal extended linker to OBPgp276 endolysin (LoGT-02) was as effective as N-terminal 
PCNP fusion [119]. Artilysin (Art-240; PCNP-λSa2lys endolysin) activity of greater than 3 log has 
also been demonstrated against Gram-positive bacteria (S. agalactiae, S. dysgalactiae, S. pyogenes, S. 
uberis, S. suis, S. porcinus, S. gordonii, S. sanguinis, and S. viridans) [121].
In addition, the protein transduction domains (PTDs), which facilitate protein transport across 
the eukaryotic membrane, have been used to engineer endolysin [94, 122, 123]. Fusion of endo-
lysin with PTD is highly effective in reducing S. aureus burden in epithelial cell lines when 
compared to non-PTD endolysins [94, 123]. Catalytic peptides can also enhance the properties 
of a lysin as shown by fusing the Cecropin A peptide (residues 1–18) to the OBPsp279 lysin, 
which targets A. baumannii and P. aeruginosa during the phage growth [124]. More clinical trial 
data are needed to assess the safety and efficacy of these lysins.
9. Concluding remarks
Given the wide spread MDR bacteria and scarcity of new antibiotics in drug development 
pipeline, alternative options have to be explored urgently. As an alternative option, phage 
therapy is reattracting worldwide attentions. It is clear that phage therapy has several advan-
tages in targeting against bacterial infections over conventional antibiotics [39, 125]: (1) phage 
is natural killer of bacteria that dictates its unique target specificity; (2) phage multiplies 
within bacteria host until host is lysed in a self-dosing manner; (3) phage shows efficacy to 
bacteria of MDR and (4) phage is environmentally friendly. Moreover, co-administration of 
phage or phage cocktail with antibiotics demonstrates synergistic effect over each individual 
treatment and increases antibiotics sensitivity from previous reports as reviewed in this chap-
ter. However, as live virus, safety concern of phage therapy, due to the gap of deep under-
standing of phage-bacteria-human interaction network, is not easily cleared in the Western 
countries though former Soviet Unions accumulated a lot of empirically successful clinical 
reports in the nearly past 50 years.
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Quality control of phage therapy based on Western medicine criteria has to be met. A small 
scale and strict quality control of a phage cocktail for treatment of P. aeruginosa and S. aureus 
infections was conducted in Belgium that included sequencing of whole phage genomes to 
verify the lack of toxin-encoding genes, confirmation of lytic phage property, lack of temper-
ate phage, stability, removal of pyrogen, sterility and cytotoxicity [126]. This small-scale pilot 
study may set a foundation of standard in the Western countries for large-scale controlled 
clinical trials for phage therapy. Phage engineering can be employed to keep bacterial kill-
ing property but bypass lysis induced endotoxin release and related side effect [127]. More 
recently, human humoral immune response against phage therapy showed that anti-phage 
antibodies (Abs), including IgM, IgG and IgA, were detected in patient sera when staphylo-
coccal MS-1 phage cocktail was used for treatment [128]. Interestingly, these anti-phage Abs 
did not compromise the final efficacy [128].
However, it seems that big pharmaceuticals are currently not interested in phage therapy, 
investment cost burden and patent filing may be another key considerations besides safety 
concern. To remove the worries from live virus-based therapy, phage-derived proteins 
(VAPGHs and endolysins) may become an option as these proteins also show the specificity 
and lytic efficiency against Gram-positive bacteria, albeit less efficient against Gram-negative 
bacteria due to the presence of OM cell wall.
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